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Immunohistochemical study of androgen, 
estrogen and progesterone receptors in 
salivary gland tumors
Abstract: The aim of this work was to study the immunohistochemi-
cal expression of androgen receptor, estrogen receptor and progesterone 
receptor in pleomorphic adenomas, Warthin’s tumors, mucoepidermoid 
carcinomas and adenoid cystic carcinomas of salivary glands. A total of 
41 pleomorphic adenomas, 30 Warthin’s tumors, 30 mucoepidermoid 
carcinomas and 30 adenoid cystic carcinomas were analyzed, and the im-
munohistochemical expression of these hormone receptors were assessed. 
It was observed that all cases were negative for estrogen and progesterone 
receptors. Androgen receptor was positive in 2 cases each of pleomorphic 
adenoma, mucoepidermoid carcinoma and adenoid cystic carcinoma. In 
conclusion, the results do not support a role of estrogen and progesterone 
in the tumorigenesis of pleomorphic adenomas, Warthin’s tumors, muco-
epidermoid carcinomas and adenoid cystic carcinomas. However, andro-
gen receptors can play a role in a small set of salivary gland tumors, and 
this would deserve further studies. 
Descriptors: Receptors, androgen; Receptors, estrogen; Receptors, 
progesterone; Salivary gland neoplasms.
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Introduction
Androgen, estrogen and progesterone, acting 
through specific receptors, play an important role in 
the growth and development of several tumors, in-
cluding breast, endometrium, and prostate carcino-
mas.1,2 Additionally, patients with breast carcinomas 
positive to estrogen receptor (ER) and progesterone 
receptor (PgR) have been treated with antagonist 
hormones and shown decreased recurrences and 
higher survival rates. Similar results have been re-
ported in patients with prostate cancer positive to 
androgen receptor (AR).3,4
In salivary gland tumors, ER, PgR and AR ex-
pression has been described in several studies.2,5-11 
However, there are great disparities in the literature, 
possibly because of the variations in the technique 
employed, which includes fixation of the tissue, anti-
gen retrieval and scoring criteria, and/or in the type 
of antibodies used. We sought to investigate the im-
munohistochemical expression of ER, PgR and AR 
in a large sample of pleomorphic adenomas (PA), 
Warthin’s tumors (WT), mucoepidermoid carcino-
mas (MEC) and adenoid cystic carcinomas (ACC) of 
salivary glands, regarding particularly the tumori-
genesis role of these receptors. 
Methods
Files of the Department of Pathology, Londrina 
Cancer Institute, Paraná State, Brazil, from 1972 to 
2001 were retrieved and 496 cases of salivary gland 
tumors were analyzed.12 The last 41 cases of PA 
and the last 30 cases of WT, MEC and ACC were 
selected for immunohistochemical evaluation. PA 
were classified as stroma-rich, cell-rich and classic 
(balanced amount of epithelial and stromal compo-
nents),13 WT were classified as stroma-rich, stroma-
poor and classic, MEC were classified as low-grade, 
intermediate-grade and high-grade according to 
Ellis, Auclair14 (1996), and ACC were classified as 
cribriform, tubular and solid.
Sections from formalin-fixed and paraffin-em-
bedded tissue were cut with 3 µm thickness and 
mounted on glass slides. The tissues were deparaf-
finized, rehydrated through graded concentrations 
of alcohol to distilled water. For antigen retrieval of 
progesterone receptor, the slides were transferred to 
a sodium citrate buffer (pH 6.0), and heated twice 
for 12 min in a 750 W microwave oven. For estrogen 
receptor and progesterone receptor, a Tris-EDTA 
pH 9.0 solution was used in a pressure cooker for 
antigen retrieval. Slides were cooled at room tem-
perature for 20 min. Endogenous peroxidase was 
blocked by incubation in a 0.05% solution of hy-
drogen peroxide for 30 min. The sections were incu-
bated overnight at 4°C with the following primary 
antibodies: anti-Androgen receptor (clone AR441, 
1/50 dilution, Dako, Carpinteria, CA, USA), anti-
Estrogen receptor (clone 1D5, 1/50 dilution, Dako, 
Carpinteria, CA, USA) and anti-Progesterone recep-
tor (clone PgR 636, 1/50 dilution, Dako, Carpinte-
ria, CA, USA). The slides were washed in phosphate-
buffered saline (PBS) and incubated with a dextran 
polymer reagent conjugated with peroxidase and 
secondary antibody (Envision+, Dako, Carpinteria, 
CA, USA) for 1 h and subsequently reacted with 
3,3’-diaminobenzidine and counterstained with 
Carazzi’s hematoxylin. Positive and negative con-
trols were included in all reactions.
Immunoreactivity was evaluated semiquantita-
tively under a light microscope and scored as nega-
tive (0-5% of positive cells), weak (6-50% of positive 
cells) and strong (> 50% positive cells). Statistical 
comparisons between variables were performed with 
Fisher’s exact test and the chi-square test.
This study was approved by the ethical commit-
tee of the Piracicaba Dental School, University of 
Campinas.
Results
From 41 cases of PA, 25 (61%) were females and 
16 (39%) males, with a mean age of 46.4 years, 
ranging from 16 to 75 years. Thirty cases were lo-
cated in the parotid gland, 6 in the submandibular 
and 5 in minor salivary glands. The majority of WT 
were in males (24 cases, 80%), all cases were located 
in the parotid gland and the mean age was 56 years, 
ranging from 42 to 78 years. Sixteen cases (53.3%) 
of MEC were in males and 14 (46.7%) were in fe-
males, the mean age was 51.3 years, ranging from 5 
to 81 years. Nineteen cases of MEC were located in 
the parotid, 3 in the submandibular and 8 in minor 
salivary glands. Regarding the 30 cases of ACC, 15 
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(50%) were in males, the mean age was 52.4 years, 
ranging from 28 to 88 years. Eight ACC cases were 
located in the parotid, 2 in the submandibular and 
20 in minor salivary glands (Table 1).
According to the histopathological examination, 
22 cases (55%) of PA were classified as stroma-rich, 
13 (30%) as cell-rich and 6 (15%) as classic. Seven-
teen cases (56.7%) of WT were classified as classic, 
10 (33.3%) as stroma-poor and 3 (10%) as stroma-
rich. Fifteen cases (50%) of MEC were classified as 
low-grade, 3 (10%) as intermediate-grade and 12 
(40%) as high-grade. Cribriform pattern was the 
most common subtype of ACC with 15 cases (50%), 
followed by the solid subtype with 8 cases (26.7%) 
and by the tubular pattern with 7 cases (23.3%).
Immunohistochemistry for ER and PR were neg-
ative in all cases studied. AR was positive in only 
2 of 41 cases of PA (Figure 1 - A,D), negative in all 
WT, positive in 2 of 30 cases of MEC (Figure 1 - 
B,E), and in 2 of 30 cases of ACC (Figure 1 - C,F). 
Of the 2 cases positive for AR in PA, one was classi-
fied as classic and the other as cell-rich. Both MEC 
positive cases were high-grade tumors and both 
ACC were of the cribriform type. 
Discussion
It’s well known that hormonal therapy is very 
useful in the treatment of breast and prostate can-
Table 1 - Demographic data of 41 cases of pleomorphic adenoma (PA), 30 cases of Warthin’s tumor (WT), 30 cases of muco-
epidermoid carcinoma (MEC) and 30 cases of adenoid cystic carcinoma (ACC).
Age Gender Location
Mean age Age range Male Female Parotid Submandibular Minor
Pleomorphic Adenoma 46.4 16-75 16 25 30 6 5
Warthin’s Tumor  56.0 42-78 24  6 30 0 0
Mucoepidermoid Carcinoma 51.3  5-81 16 14 19 3 8
Adenoid Cystic Carcinoma 52.4 28-88 15 15  8 2  20
Figure 1 - Histological features of pleomorphic adenoma (A), mucoepidermoid carcinoma (B) and adenoid cystic carcinoma 
(C) (hematoxylin and eosin, original magnification X 200). Immunohistochemical positivity for androgen receptor (AR) in pleo-
morphic adenoma (D), mucoepidermoid carcinoma (E) and adenoid cystic carcinoma (F) (original magnification X 200).
A B C
E FD
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cer.3,4 However, in spite of the confirmed expression 
of sex hormone receptors in other types of cancer 
such as endometrial carcinomas,15 carcinomas of the 
thyroid,16 renal cell carcinomas,17 malignant melano-
ma,18 and meningiomas,19 the efficacy of hormonal 
therapy in these tumors has not yet been established. 
Studies with ER, PgR and AR in salivary gland 
tumors are conflicting (Tables 2 and 3). ER expres-
sion was detected by Jeannon et al.20 (1999) in 3 of 
10 MEC, 3 of 6 ACC and in 4 of 10 PA, while Nass-
er et al.2 (2003) reported 1 of 10 MEC positive for 
ER, and, in a study by Glas et al.1 (2002), 19% of 
PA demonstrated immunoreactivity for ER. On the 
other hand, several studies,8,9,21-24 including ours, 
did not reveal ER expression in the cases studied. 
PgR has been reported more frequently than ER. 
Shick et al.9 (1995) and Dori et al.22 (2000), study-
ing ACC, found 50% and 6.9% of PgR positive cas-
es, respectively. Jeannon et al.20 (1999) related one 
positive case out of 10 cases of PA, but all 10 cases 
of MEC and 6 of ACC were negative. Nasser et al.2 
(2003) related one positive MEC, but all ACC, PA 
and WT were negative. Teymoortash et al.24 (2001) 
found 6 cases positive for PgR in 9 cases of WT, but 
all 5 cases of PA were negative. Glas et al.1 (2002) 
reported 60 positive cases of PA out of 69 studied, 
and also suggested that PgR could be a prognostic 
factor in recurrent PA of the parotid gland. In the 
present study, we did not find PgR expression in PA, 
WT, MEC and ACC. 
There are few studies of AR in PA, WT, MEC 
and ACC. Moriki et al.25 (2001) related that all these 
tumors were negative for AR. Nasser et al.2 (2003) 
did not find AR expression in benign salivary gland 
Table 3 - Summary of the reports of estrogen receptor (ER), progesterone receptor (PgR) and androgen receptor (AR) in muco-
epidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC).
Authors Year
MEC ACC
No. of cases ER + PgR + AR + No. of cases ER + PgR + AR +
Miller et al.21 1994 np np np np  5 0 np np
Shick et al.9 1995 np np np np 12 0 6 np
Jeannon et al.20 1999 10 3 0 np  6 3 0 np
Dori et al.22 2000 np np np np 29 0 2 np
Moriki et al.25 2001 6 np np 0  8 np np 0
Nasser et al.2 2003 10 1 1 2 10 0 0 2
Pires et al.8 2004 136 0 np np 72 0 np np
Our study 2009 30 0 0 2 30 0 0 2
np: not performed.
Table 2 - Summary of the reports of estrogen receptor (ER), progesterone receptor (PgR) and androgen receptor (AR) in pleo-
morphic adenoma (PA) and Warthin’s tumor (WT).
Authors Year
PA WT
No. of cases ER + PgR + AR + No. of cases ER + PgR + AR +
Lamey et al.23 1987  4 0 0 np np np np np
Jeannon et al.20 1999 10 4 1 np np np np np
Moriki et al.25 2001 10 np np 0 10 np np 0
Teymoortash et al.24 2001  5 0 0 np 9 0 6 np
Glas et al.1 2002 69 13 60 np np np np np
Nasser et al.2 2003 10 0 0 0 10 0 0 0
Our study 2009 41 0 0 2 30 0 0 0
np: not performed.
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tumors, but related 2 of 10 MEC and 2 of 10 ACC 
positive for AR. In our study, AR was seen in only 
2 cases each, of 41 PA, 30 MEC and 30 ACC. In 
contrast to the low or absent AR expression in PA, 
MEC, WT and ACC, it has been described to be 
positive in almost all salivary duct carcinomas2,10,25 
and therefore potentially useful for their diagnosis 
in biopsy or cytological samples.25,26 Additionally, 
Locati et al.27 (2003) reported a complete remission 
with androgen-deprivation therapy in a recurrent 
adenocarcinoma of the parotid gland that expressed 
AR. Considering this data of remission with an an-
drogen-deprivation therapy, some cases that are pos-
itive for AR, particularly the recurrent ones, should 
be better studied and considered as potential targets 
for treatment with anti-androgen drugs. On the oth-
er hand, although AR has been described in salivary 
gland tumors, particularly in malignancies, it’s not 
known if this fact is due to a role of androgen in the 
pathogenic process or if it simply represents an epi-
phenomenon of the malignant transformation.2 
Conclusions
Our results suggest that ER and PgR seem to 
be not important to the tumorigenesis of PA, WT, 
MEC and ACC. Nevertheless, androgen receptors 
may play a role in a small group of salivary gland 
tumors, and should be better investigated specially 
correlating with their clinico-pathological features. 
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